DarioHealth Corp

NASDAQ DRIO

Data sourced from

and

Download Data

DarioHealth Corp Long-Term Debt to Equity Ratio 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 48.56%

DarioHealth Corp Long-Term Debt to Equity Ratio 2 year CAGR is 48.56% for the Trailing 12 Months (TTM) ending March 31, 2024. The long-term debt to equity ratio measures the proportion of a company's long-term debt to its shareholders' equity. It is calculated by dividing the long-term debt by the shareholders' equity. This ratio helps assess the company's long-term solvency and its reliance on debt financing. A higher ratio indicates a higher level of debt relative to equity, which can increase the company's financial risk and affect its ability to meet long-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

DarioHealth Corp Long-Term Debt to Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.24.

NASDAQ: DRIO

DarioHealth Corp

CEO	Mr. Erez Raphael
IPO Date	Oct. 6, 2014
Location	United States
Headquarters	18 West 18th Street, New York, NY, United States, 10011
Employees	276
Sector	Healthcare
Industry	Health information services

Description

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Key trends